HCA Healthcare, Inc. (NYSE:HCA) Shares Sold by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG lowered its position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,313 shares of the company's stock after selling 918 shares during the quarter. J. Safra Sarasin Holding AG's holdings in HCA Healthcare were worth $3,396,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC boosted its holdings in HCA Healthcare by 96.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,135 shares of the company's stock valued at $3,342,000 after purchasing an additional 5,469 shares during the period. Mirabella Financial Services LLP bought a new stake in HCA Healthcare in the fourth quarter worth $10,569,000. Natixis lifted its position in HCA Healthcare by 51.4% in the fourth quarter. Natixis now owns 128,586 shares of the company's stock valued at $38,595,000 after purchasing an additional 43,628 shares during the last quarter. Norinchukin Bank The raised its stake in shares of HCA Healthcare by 1.0% during the fourth quarter. Norinchukin Bank The now owns 7,196 shares of the company's stock valued at $2,160,000 after acquiring an additional 74 shares during the last quarter. Finally, Ossiam boosted its holdings in HCA Healthcare by 12.0% in the fourth quarter. Ossiam now owns 4,345 shares of the company's stock valued at $1,304,000 after acquiring an additional 467 shares in the last quarter. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

NYSE HCA traded down $13.72 on Friday, hitting $327.69. The company had a trading volume of 2,803,570 shares, compared to its average volume of 1,398,773. The company has a market capitalization of $80.68 billion, a PE ratio of 14.92, a PEG ratio of 1.10 and a beta of 1.48. The company has a debt-to-equity ratio of 69.07, a current ratio of 1.08 and a quick ratio of 0.97. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14. The company's fifty day moving average price is $329.61 and its 200-day moving average price is $332.87.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $6.45 EPS for the quarter, beating analysts' consensus estimates of $5.77 by $0.68. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. The company had revenue of $18.32 billion for the quarter, compared to the consensus estimate of $18.26 billion. During the same period in the prior year, the firm posted $5.36 EPS. As a group, analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 16th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.88%. HCA Healthcare's dividend payout ratio (DPR) is presently 13.11%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada lowered their target price on shares of HCA Healthcare from $405.00 to $384.00 and set an "outperform" rating for the company in a report on Monday, January 27th. KeyCorp dropped their price target on shares of HCA Healthcare from $420.00 to $370.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 7th. Truist Financial dropped their price objective on HCA Healthcare from $430.00 to $390.00 and set a "buy" rating for the company in a research note on Monday, January 6th. Barclays reduced their price target on shares of HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Finally, Guggenheim initiated coverage on shares of HCA Healthcare in a report on Wednesday, April 9th. They issued a "neutral" rating for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, HCA Healthcare has an average rating of "Moderate Buy" and a consensus price target of $381.67.

Insider Buying and Selling at HCA Healthcare

In other news, SVP Jennifer Berres sold 9,533 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $322.59, for a total value of $3,075,250.47. Following the sale, the senior vice president now directly owns 15,412 shares in the company, valued at $4,971,757.08. This represents a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.